Consorci Hospitalari De Vic
- Address
- Carrer De Francesc Pla El Vigata 1, 08500 Vic, Spain
Immune System Diseases
The department of Allergology at Consorci Hospitalari De Vic is conducting trials that target immune system disorders related to pollen allergy, focusing on patients with allergic rhinoconjunctivitis with or without asthma.
- Grass pollen allergen immunotherapy efficacy
- Olive pollen allergen immunotherapy efficacy
- Symptom‑medication score monitoring via mobile application
- Placebo‑controlled study design
These investigations aim to improve therapeutic options for allergic patients and are being carried out at the Vic hospital, involving three investigators across two clinical studies.
Respiratory Tract Diseases
Research at the site also addresses respiratory tract diseases by evaluating how allergen immunotherapy can reduce symptoms of rhinitis and asthma triggered by grass and olive pollen.
- Clinical efficacy of grass/olive AIT
- Change in conjunctival provocation test reactivity
- Double‑blind, randomised, controlled methodology
- Open‑label follow‑up phase
The goal is to demonstrate that targeted immunotherapy can lessen respiratory allergy burden, offering a potential new standard of care for patients in the region.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 13 of 14 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1LETI Pharma S.L.U.2active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1LETI Pharma S.L.U.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Consorci Hospitalari De Vic
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Comparison of Adjuvant Elacestrant with Standard Endocrine Therapy in High-Risk ER+/HER2- Early Breast Cancer | WSG Westdeutsche Studiengruppe GmbH | Phase III | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 14 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dactylis Glomerata Pollen Extract | 2 | Unknown | 2026-06-23 | 2026-06-23 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.